{"id":10163,"date":"2025-12-07T14:45:56","date_gmt":"2025-12-07T10:45:56","guid":{"rendered":"https:\/\/medscriptum.org\/?p=10163"},"modified":"2025-12-07T14:46:50","modified_gmt":"2025-12-07T10:46:50","slug":"precise-diagnostics-of-hiv-infection","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/precise-diagnostics-of-hiv-infection\/","title":{"rendered":"Precise Diagnostics of HIV Infection"},"content":{"rendered":"<p style=\"text-align: justify\" data-path-to-node=\"1\">The development of HIV vaccines created a significant diagnostic dilemma: Vaccine-Induced Seropositivity (VISP). VISP means that vaccinated individuals produce antibodies that are virtually indistinguishable from antibodies caused by a real HIV infection using standard testing methods. This can lead to widespread false positive results, causing stress and confusion for patients.<\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"2\">A new study presents a technological breakthrough to solve this problem: a portable Point-of-Care (POC) diagnostic test that simultaneously detects four main HIV markers in 5 minutes. By integrating electrochemical sensor technology and machine learning algorithms, the test can accurately differentiate between active HIV infection and a vaccination reaction.<\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"4\"><strong>The VISP Challenge and Standard Tests<\/strong><\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"5,0,0\">Prophylactic HIV vaccines work by prompting the immune system to produce antibodies against key HIV protein components (gp120, gp41, p24)\u2014the same targets that standard diagnostic tests look for. As a result, vaccinated but uninfected individuals often receive a false-positive result on antibody-based tests. The frequency of VISP can range from <span class=\"math-inline\" data-math=\"&lt;1\\%\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">&lt;<\/span><\/span><span class=\"base\"><span class=\"mord\">1%<\/span><\/span><\/span><\/span><\/span> to <span class=\"math-inline\" data-math=\"&gt;95\\%\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">&gt;<\/span><\/span><span class=\"base\"><span class=\"mord\">95%<\/span><\/span><\/span><\/span><\/span> depending on the vaccine and test used.<\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"5,1,0\">Limitations of Standard Tests: Conventional antibody-based tests (ELISA, Western blot, rapid tests) cannot differentiate between vaccination-induced and real infection-induced antibodies. This diagnostic conflict causes severe clinical and social consequences: acute psychological distress, social stigma, prohibition from blood donation, and incorrect clinical management. While RNA-based viral load tests can confirm genuine infection, they are expensive and lab-intensive, limiting their widespread use.<\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"7\"><strong>Multiplex Electrochemical Analysis: The Breakthrough<\/strong><\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"8\">Researchers created a nanotechnology-based, multiplex electrochemical assay capable of simultaneously detecting four target markers:<\/p>\n<div class=\"horizontal-scroll-wrapper\" style=\"text-align: justify\">\n<div class=\"table-block-component\">\n<div class=\"table-block has-export-button\">\n<div class=\"table-content not-end-of-paragraph\" data-hveid=\"0\" data-ved=\"0CAAQ3ecQahcKEwjK5v7az6aRAxUAAAAAHQAAAAAQbw\">\n<table data-path-to-node=\"9\">\n<thead>\n<tr>\n<td>Marker<\/td>\n<td>Role in Diagnosis<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>p24 Antigen<\/td>\n<td>Core viral protein, appears in the earliest phase of infection.<\/td>\n<\/tr>\n<tr>\n<td>Anti-p24 Antibody<\/td>\n<td>Part of the body&#8217;s immune response to the virus.<\/td>\n<\/tr>\n<tr>\n<td>HIV-1 Viral RNA<\/td>\n<td>Direct indicator of active viral replication and multiplication.<\/td>\n<\/tr>\n<tr>\n<td>MS2 Bacteriophage RNA<\/td>\n<td>Internal control indicator to ensure assay accuracy.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify\" data-path-to-node=\"10\"><strong>How the Sensor Works:<\/strong><\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"11,0,0\">Platform: The test uses a high-tech electrochemical sensor platform based on Gold Screen-Printed Electrodes (Au-SPEs).<\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"11,1,0\">Sensing: The electrode surface is chemically modified with two types of biomolecular probes: specific antibodies (for protein targets) and antisense oligonucleotides (to capture viral RNA).<\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"11,2,0\">Signal Generation: These probes are tagged with Methylene Blue (MB), an electroactive molecule that generates an electrical signal (redox signal).<\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"11,3,0\">Detection: When a target molecule (e.g., p24 antigen or viral RNA) binds to the probe on the electrode, it changes the redox activity of Methylene Blue. This is measured by Cyclic Voltammetry as a sharp change in the redox signals, allowing researchers to accurately determine the presence\/concentration of the HIV marker in the sample. The electrodes function as highly sensitive sensors, converting a biological event (molecular binding) into an electrical signal.<\/p>\n<figure id=\"attachment_10160\" aria-describedby=\"caption-attachment-10160\" style=\"width: 2560px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10160 size-full\" src=\"https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-scaled.jpg\" alt=\"\" width=\"2560\" height=\"2443\" srcset=\"https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-scaled.jpg 2560w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-300x286.jpg 300w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-1024x977.jpg 1024w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-768x733.jpg 768w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-1536x1466.jpg 1536w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-2048x1954.jpg 2048w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-440x420.jpg 440w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-880x840.jpg 880w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-150x143.jpg 150w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-600x573.jpg 600w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-696x664.jpg 696w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-1392x1328.jpg 1392w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-1068x1019.jpg 1068w, https:\/\/medscriptum.org\/wp-content\/uploads\/2025\/12\/sciadv.adz5639-f7-1920x1832.jpg 1920w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption id=\"caption-attachment-10160\" class=\"wp-caption-text\">Science Advances<\/figcaption><\/figure>\n<p style=\"text-align: justify\" data-path-to-node=\"13\">The advantage of this high-sensitivity assay is its simplicity: a smartphone-sized, 3D-printed portable device processes samples after only a 4-minute viral lysis step. This eliminates the need for complex laboratory extraction, making the test an ideal tool for rapid diagnostics in field or resource-limited settings. This innovation fully satisfies the WHO&#8217;s ASSURED diagnostic criteria: Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free (or minimal), and Deliverable.<\/p>\n<p style=\"text-align: justify\" data-path-to-node=\"15\"><strong>Marker Selection and Clinical Validation<\/strong><\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"16,0,0\">Marker Strategy: Viral RNA appears earliest (days after infection), followed by the p24 antigen, with antibodies appearing last. RNA detection allows for the earliest detection in the &#8220;eclipse phase,&#8221; which antibody tests miss. Plasma RNA testing indicates active viral replication and infectivity.<\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"16,1,0\">Sensitivity &amp; Specificity: The analytical detection limit for the p24 antigen (<span class=\"math-inline\" data-math=\"5.88 \\text{ pg\/ml}\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">5.88<\/span><span class=\"mord text\"><span class=\"mord\">\u00a0pg\/ml<\/span><\/span><\/span><\/span><\/span><\/span>) and antibodies (<span class=\"math-inline\" data-math=\"10.96 \\text{ pg\/ml}\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">10.96<\/span><span class=\"mord text\"><span class=\"mord\">\u00a0pg\/ml<\/span><\/span><\/span><\/span><\/span><\/span>) is competitive with or exceeds existing ELISA tests. Crucially, the RNA detection limit reaches <span class=\"math-inline\" data-math=\"1250 \\text{ copies\/ml}\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">1250<\/span><span class=\"mord text\"><span class=\"mord\">\u00a0copies\/ml<\/span><\/span><\/span><\/span><\/span><\/span> with high specificity and no cross-reactivity with related viruses like Zika or Dengue.<\/p>\n<p style=\"padding-left: 40px;text-align: justify\" data-path-to-node=\"16,2,0\">Clinical Evidence: Rigorous clinical testing on 104 plasma samples (including HIV-positive, negative, vaccinated, and unvaccinated individuals) confirmed the test&#8217;s high efficacy, showing <span class=\"math-inline\" data-math=\"95\\%\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">95%<\/span><\/span><\/span><\/span><\/span> sensitivity and <span class=\"math-inline\" data-math=\"98\\%\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">98%<\/span><\/span><\/span><\/span><\/span> specificity in distinguishing HIV infection from vaccination-induced reactions.<\/p>\n<p style=\"text-align: justify\">Source: <a href=\"https:\/\/www.science.org\/doi\/10.1126\/sciadv.adz5639\" target=\"_blank\" rel=\"noopener\">Science Advances<\/a><\/p>\n<p style=\"text-align: justify\"><br style=\"font-weight: 400\" \/><br style=\"font-weight: 400\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The development of HIV vaccines created a significant diagnostic dilemma: Vaccine-Induced Seropositivity (VISP). VISP means that vaccinated individuals produce antibodies that are virtually indistinguishable from antibodies caused by a real HIV infection using standard testing methods. This can lead to widespread false positive results, causing stress and confusion for patients. A new study presents a [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":10165,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1596,1587,1659],"tags":[1589,3271],"class_list":["post-10163","post","type-post","status-publish","format-standard","has-post-thumbnail","category-internal-medicine","category-research","category-technologies","tag-diagnosis","tag-hiv-infection"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/10163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=10163"}],"version-history":[{"count":4,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/10163\/revisions"}],"predecessor-version":[{"id":10219,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/10163\/revisions\/10219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/10165"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=10163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=10163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=10163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}